0.10
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kelyniam Global
Its shares trade under the ticker KLYG. It has been listed since 3 April 2008. In the fiscal year to 31 December 2025, it reported revenue of $3.1m and a net loss of $138,555. At that date it held total assets of $1.8m and shareholders' equity of $813,328.
Kelyniam Global, Inc. operates as a medical device manufacturing company, which engages in the production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers. The company is headquartered in Collinsville, Connecticut. The company went IPO on 2008-04-03. The firm is engaged in the production of custom prosthetics utilizing computer-aided design and computer-aided manufacturing of medical-grade polymers. Its Engineering Division uses Bio-Computer Aided Design (CAD) Computer Aided Manufacturing (CAM) technology to provide replicated cranial implants to replace damaged bone structures. Its product, PEEK-Optima, is engineered for biocompatibility. Derived from the patient's computed tomography (CT) scan data, the Company's 3D BIO-CAD/CAM software is used to transfer the details found on the edge of the defect directly to the implant edge. Its K-Plans include ke24, ke72 and kp5day. The firm's emergency plan, ke24, provides precision-replicated, patient-specific cranial implants in approximately 24 hours. The ke72 plan provides the implants in approximately 72 hours. Its kp5day is a physical implant verification service.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 3 Apr 2008
- Website
- kelyniam.com ↗
- Head office
- 1100 NORTH UNIVERSITY AVENUE, LITTLE ROCK, AR, 72207
- Incorporated in
- NV
- Classification
- Services-Engineering Services
Leadership
Pay as last reported
- Mr. Ross BjellaChairman of the Board, Chief Executive Officer, since 2018
- Mr. Terrance KurtenbachChief Financial Officer
- Mr. Christopher BreaultChief Operating Officer, since 2018
- Mark ChenowethVice President - Sales and Marketing
- Mr. Mark SmithVice President - Sales and Business Development
- Nick BreaultVice President - Production
- Mr. James BarrowGeneral Counsel, Director of Quality and Regulatory
- Dr. Christopher MiruckiChief Medical Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kelyniam Global Inc possesses several strengths that contribute to its competitive advantage and market position. These strengths include:
Weaknesses
- Despite its strengths, Kelyniam Global Inc also faces certain weaknesses that hinder its growth and success. These weaknesses include:
Opportunities
- Kelyniam Global Inc can capitalize on several opportunities available in the market to further its growth and expand its market share. These opportunities include:
Threats
- Kelyniam Global Inc must also be aware of potential threats that could negatively impact its business operations. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.